<DOC>
	<DOCNO>NCT02025712</DOCNO>
	<brief_summary>The purpose study determine whether exemestane plus everolimus effective treatment patient achieve disease stabilization induction chemotherapy hormone-receptor positive metastatic breast cancer .</brief_summary>
	<brief_title>Exemestane Plus Everolimus Hormone-receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>Postmenopausal woman HR-positive , HER2-negative metastatic breast cancer achieve clinical benefit induction chemotherapy visceral disease sign ( ) and/or symptom ( ) recruit receive study maintenance treatment everolimus plus exemestane .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Postmenopausal woman define protocol page 9 ; Histologically and/or cytologically confirm invasive breast cancer stage IV disease accord AJCC ; Confirmed ER/PRpositive , HER2 negative tumor ; Disease progression follow prior endocrine therapy tamoxifen nonsteroidal aromatase inhibitor , define protocol , prior standard care ( SOC ) induction chemotherapy Patient document evidence visceral disease ( include limit hepatic involvement pulmonary lymphangitic spread tumor ) sign ( ) and/or symptom ( ) prior SOC induction chemotherapy achieve disease stabilization SOC induction chemotherapy , confirm upon 2 consecutive routine tumor assessment ; ECOG performance status ≤ 2 Karnofsky performance status ≥ 50 % prior start study treatment ; Adequate organ function prior start study treatment define protocol ; Able swallow retain oral medication ; Able give write informed consent ; Male patient ; Metastatic disease limit bone soft tissue history visceral metastasis ; History brain CNS metastases ; Previous treatment exemestane , unless exemestane administer adjuvant setting stop &gt; 1 year metastatic relapse ; Untreated SOC chemotherapy invasive breast cancer stage IV disease accord AJCC treat SOC chemotherapy invasive breast cancer stage IV disease accord AJCC without clinical benefit ; History neurological psychiatric disorder ; Any serious cardiovascular disease previous 6 month ; Impairment gastrointestinal function gastrointestinal disease ; Patients uncontrolled infection ; Patients active , bleed diathesis oral antivitamin K medication ( except low dose coumadin define 1 mg day ) ; Chronic treatment systemic steroid another immunosuppressive agent ; Patients preexist peripheral neuropathy &gt; grade 1 ; Patients hepatitis B and/or hepatitis C carrier ; Known human immunodeficiency virus infection ; Prior exposure mTOR inhibitor ; Hypersensitivity rapamycin similar compound ; Patients take medication know inhibitor inducer CYP3A4 and/or PgP include study ; Prior treatment investigational agent within precede 4 week ; Other condition judgment investigator , would make patient inappropriate entry study . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>